XORTX Announces Filing and Mailing of Meeting Documents
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company dedicated to creating innovative therapies for progressive kidney disease, has made important announcements regarding its upcoming annual and special meeting of shareholders. The management information circular for this meeting is now available on the Company’s corporate website, reflecting their commitment to transparency and engagement with shareholders.
Availability of Meeting Documents
The management information circular includes essential information about the upcoming meeting, and shareholders are encouraged to review these materials carefully. This circular can be accessed not only on XORTX's official site but also on SEDAR+ and the SEC’s websites. By providing these documents, XORTX ensures that all shareholders have the necessary information to make informed voting decisions.
Important Meeting Details
XORTX has set the date for the annual and special meeting on September 12 at 10:00 AM (Calgary Time). The meeting will be held at the Company’s offices located at 3710 – 33rd Street NW. It is crucial for shareholders to participate and cast their votes, emphasizing that every vote counts, regardless of the number of shares owned.
Voting Process and Guidelines
Shareholders are urged to act promptly, as the voting deadline is 10:00 AM on September 10. For assistance, XORTX’s strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, is available to help with any voting inquiries. Shareholders can contact them by calling 1-877-452-7184 or emailing assistance@laurelhill.com.
Clarification of Important Information
The circular also includes a clarification regarding the participation of directors in previous board meetings. It specifically addresses the misreported attendance record of Patrick Treanor, who was not a board member during those meetings in 2023. This correction aims to provide shareholders with an accurate account of board activities.
Overview of XORTX Therapeutics Inc.
XORTX is leading the way in developing pharmaceutical solutions, with two significant products currently in late-stage clinical development. The primary program, XRx-008, targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), while the secondary program, XRx-101, focuses on acute kidney and organ injuries associated with infections, including COVID-19. Additionally, XORTX is advancing XRx-225, which is in the pre-clinical stage and aims to address Type 2 Diabetic Nephropathy.
Clinical Development Focus
The Company’s dedication to innovative therapies is rooted in its understanding of aberrant purine metabolism and the role of xanthine oxidase inhibition in treating various kidney diseases. With a commitment to enhancing patient quality of life, XORTX continues to diligently progress through its clinical development stages.
Contact Information for Shareholders
For any questions, shareholders can reach out to Allen Davidoff, CEO, at adavidoff@xortx.com or +1 403 455 7727. Nick Rigopulos, Director of Communications, is also available for inquiries at nick@alpineequityadv.com or +1 617 901 0785. Additionally, Kim Golodetz from LHA Investor Relations can assist at kgolodetz@lhai.com or +1 212 838 3777.
Frequently Asked Questions
What is the purpose of the XORTX annual meeting?
The annual meeting allows shareholders to receive updates from the company, discuss financial performance, and vote on important business matters.
When is the deadline for shareholders to vote?
Shareholders must vote by 10:00 AM (Calgary Time) on September 10.
How can shareholders access the management circular?
Shareholders can find the management circular on XORTX's website, as well as through SEDAR+ and SEC websites.
Who should shareholders contact for voting assistance?
For help with voting, shareholders should contact Laurel Hill Advisory Group.
What are the main products in development by XORTX?
XORTX is working on XRx-008 and XRx-101, which target kidney diseases and related conditions, along with another program in the pre-clinical stage focusing on diabetic nephropathy.
